Longest-living people swear by 'Hara Hachi Bu' dieting trick
Italy, Japan, and Costa Rica might appear very different on the surface, but they are actually connected by a surprising common trait. These countries boast three of the globe's six exclusive 'Blue Zones' where inhabitants are reportedly 10 times more likely to live to 100 than anywhere in the United States.
However, not living in these longevity hubs isn't a reason to despair. A potentially game-changing key to the residents' long lives has recently been revealed—it's all about a strict practice called the '80% trick' or 'Hara Hachi Bu.'
This dietary rule is particularly unfavourable for those who want to eat three large meals daily. People in Blue Zones usually have a small meal later in the day, deliberately stopping at about 80% fullness, hence the name of the rule.
It's said this practice helps prevent the common 'food coma' feelings that can occur after overeating, while also enabling residents to stay active throughout the day. It is mainly practised by Okinawans on one of Japan's smallest islands, as noted by Blue Zones explorer Dan Buettner.
According to a previous Mirror report, he wrote online: "The secret to eating in moderation in the long run is emulating the environment and habits of the Okinawan people. There is a significant calorie gap between when an American says, 'I'm full' and an Okinawan says, 'I'm no longer hungry'."
Previous research suggests that they exist in a 'calorie deficit', consuming only 1,900 calories instead of the usual 2,000 to 2,500, which is associated with a reduced risk of diseases related to ageing.
These views are echoed by Dr Deborah Lee, a GP at Dr Fox Pharmacy, too. She told the Mirror that eating less may even help to reduce ageing.
"Imagine what 80% of your meal would look like, and aim to leave 20% behind," she said previously. "Calorie restriction is believed to slow the ageing process. Eating less lowers the metabolic rate.
"With less metabolic processes underway, less oxidation is taking place. Oxidative stress probably underpins the development of many of the chronic diseases we see today – heart disease, cancer, type-2 diabetes and dementia."
Dr Lee suggested that eating slowly can help one adhere to the 80% rule. Research supports this theory, with a 2012 study indicating that slower eating is associated with increased satisfaction and less hunger between meals.
She continued: "Nutritionists believe that when you look at your plate, if you eat mindfully, eating slowly and chewing every mouthful thoroughly, you can feel satisfied by eating only 80% of that is on your plate.
"The diet has many benefits. You don't have to count calories, and no foods are absolutely forbidden. It can fit in with your work and social schedule. You are still eating large amounts of healthy foods and getting good nutrition."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mirror
25 minutes ago
- Daily Mirror
Brits considering 'cosmetic cowboy' surgery abroad to be warned of risks on TikTok
More people are using social media apps like TikTok to research potentially risky operations abroad as they are often cheaper or more readily available than in the UK People considering cosmetic procedures abroad will soon be given advice on how to avoid risks by influencers. The Department of Health and Social Care is set to launch a campaign alongside TikTok to help people make safer choices. It follows the government announcing a major crackdown on 'Wild West' cowboy cosmetics in the UK in a victory for the Mirror 's surgery campaign. More people are using social media apps like TikTok to research potentially risky operations - like hair transplants and dental work - abroad as they are often cheaper or more readily available than in the UK but are often presented with slick marketing campaigns that do not highlight the dangers of the surgery. It comes amid a major change to drink-driving limit under huge shake-up of road safety laws plan. Health Minister Karin Smyth said: 'Too many people are being left with life-altering injuries after going abroad for medical procedures, without access to proper advice or safeguards. Often drawn in by deals too good to be true and promoted by influencers – some of whom have never been to the practice in question. 'By partnering with TikTok, we're helping people make safer, more informed choices before they go under the knife – wherever that may be. We're determined to protect patients, ease pressure on the NHS and make sure taxpayers are not left paying the price when things go wrong.' The Mirror is demanding that all beauty clinics offering potentially dangerous procedures, including 'high risk' treatments such as BBLs, liposuction, surgical facelifts and surgical eye lifts, are licensed by the Quality Care Commission. The new government campaign warns that when it comes to cosmetic surgery abroad, the lowest price can come at the highest cost. It urges people to think beyond the slick brochures and marketing, and to consider clinical standards, complication risks, and language barriers. It will suggest potential patients speak to a UK doctor, take out travel insurance, and steer clear of package holidays that bundle in procedures. The medics will provide a check list to go through before considering booking a procedure abroad: research thoroughly, check the clinic's regulation and the surgeon's credentials, know the full cost, and understand the aftercare. The online campaign is part of wider government efforts to curb medical tourism. Work is also underway to stop events in the UK that promote procedures abroad and to improve patient care from initial consultations to post-surgery recovery.
Daily Mirror
an hour ago
- Daily Mirror
Mounjaro weight loss drug price to surge by 170% for Brits - except for ONE customer
Eli Lilly is increasing the UK price of its weight-loss drug Mounjaro Eli Lilly is set to significantly hike the UK price of its weight-loss and diabetes medication Mounjaro, with some dosages expected to see a staggering 170 percent increase starting from September. The pharmaceutical giant has justified the price surge as an effort to "address pricing inconsistencies compared with other developed countries, including in Europe" and to ensure equitable global contributions towards funding medical research. The sharpest rise will affect the month's supply of the drug's highest doses, which will soar from £122 to £330. Smaller doses will experience increases ranging from 45 to 138 percent. It comes after a man, 30, puts shoulder pain down to gym aches, then doctors ask where he'd like to die. Despite these changes, Lilly has assured that the NHS will not be affected by the new list prices, pledging to maintain the current rates to preserve uninterrupted patient access. Private healthcare providers, who also offer the medication, will face the new prices but have the option to negotiate confidential discounts directly with Eli Lilly. This development occurs amidst political debates in the US, where ex-president Donald Trump has lambasted what he deems "foreign freeloaders" for enjoying lower pharmaceutical costs while Americans bear much higher expenses. In one address, he highlighted obesity treatments, recounting how a friend in London acquired the "fat shot drug" at a fraction of the US cost, reports the Daily Record. Research from the Rand Corporation indicates that drug prices in the US are typically almost triple those in several other advanced nations. The pharmaceutical sector has been mobilising to combat the potential danger of a "most favoured nation" strategy, which could tie American pricing to international rates. Lilly highlighted that the UK was amongst the earliest markets to receive Mounjaro and emphasised that its initial focus had been on delivering the medication to diabetic patients swiftly. "At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation," the firm stated. Talks between pharmaceutical companies and the UK Government regarding NHS drug costs have grown increasingly fraught, with deliberations about modifications to a clawback levy on pharmaceutical sales extending well beyond agreed timelines. The Government's latest proposals featured plans to increase spending on medications, though industry chiefs voiced exasperation over the absence of specifics or clarity regarding whether this would involve purchasing additional medicines or paying elevated prices for current treatments. The National Institute for Health and Care Excellence (NICE) has endorsed Mounjaro for as many as 3.4 million individuals across England. Nevertheless, worries about cost-effectiveness resulted in an arrangement for a staged introduction, beginning with approximately 250,000 patients presenting the most urgent clinical requirements during the initial three years. NHS England has assured that the forthcoming price alterations will not impact the provision of the medication to qualified patients suffering from obesity or diabetes. "Mounjaro is a cost-effective and valuable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers," NHS England stated. The adjustments bring the UK's pricing more in line with the European mean, occurring amidst a period when drug manufacturers are acutely aware of how varying international prices might influence upcoming policy choices in the US.
Daily Record
7 hours ago
- Daily Record
Price of weight loss drug Mounjaro to rise - how much more users will pay
Eli Lilly will raise UK prices for Mounjaro by up to 170 percent to 'address pricing inconsistencies compared with other developed countries, including in Europe' Eli Lilly is sharply increasing the UK price of its weight-loss and diabetes drug Mounjaro, with the cost of some doses set to rise by as much as 170 percent from September. The pharmaceutical company said the move is intended to 'address pricing inconsistencies compared with other developed countries, including in Europe' and ensure a fairer global contribution to funding medical innovation. The most dramatic increase will see the month's supply of the highest doses of the drug jump from £122 to £330. Lower doses will rise by between 45 and 138 percent. However, Lilly stressed that the new list prices will not apply to the NHS, with the company continuing to supply the health service at the existing rate to avoid disrupting patient access. Private healthcare providers, who also prescribe the drug, will be subject to the increase but can negotiate confidential discounts with the company. The move comes against the backdrop of political pressure from the United States, where former president Donald Trump has criticised what he calls 'foreign freeloaders' benefiting from lower drug prices abroad while Americans pay substantially more. In a speech, he singled out obesity treatments, saying a friend in London had bought the 'fat shot drug' for far less than in the US. Research by the Rand Corporation suggests that US drug prices are, on average, almost three times higher than those in many other advanced economies. The pharmaceutical industry has been working to counter the potential threat of a 'most favoured nation' policy, which could peg American prices to those charged internationally. Lilly noted that the UK was one of the first markets where it launched Mounjaro and said its initial priority had been to get the medicine to diabetes patients quickly. 'At launch, Lilly agreed to a UK list price that is significantly below the European average to prevent delays in NHS availability. With changes in the environment and new clinical evidence supporting the value of Mounjaro, we are now aligning the list price more consistently to ensure fair global contributions to the cost of innovation,' the company said. Negotiations between drugmakers and the UK government over NHS medicine costs have been tense, with discussions about changes to a clawback tax on drug sales dragging past agreed deadlines. The government's most recent proposals included plans to spend more on medicines, but industry leaders expressed frustration at the lack of detail or clarity on whether this would mean buying more medicines or paying higher prices for existing ones. The National Institute for Health and Care Excellence (NICE) has recommended Mounjaro for up to 3.4 million people in England. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. However, concerns over affordability led to an agreement for a phased rollout, starting with around 250,000 patients who have the highest clinical need over the first three years. NHS England confirmed that the upcoming price changes would not affect how it provides the drug to eligible patients with obesity or diabetes. 'Mounjaro is a cost-effective and valuable tool to support people to reach a healthier weight and the wider health and lifestyle benefits that offers,' it said. The changes place the UK price closer to the European average and come at a time when pharmaceutical companies are increasingly conscious of how international price differences could shape future US policy decisions.
